Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation

Published:2018-09-30 Issue:11 Volume:7 Page:728-738
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Cirincione Brenda¹,Kowalski Kenneth²³,Nielsen Jace²,Roy Amit¹,Thanneer Neelima¹,Byon Wonkyung⁴,Boyd Rebecca⁴,Wang Xiaoli¹,Leil Tarek¹,LaCreta Frank¹,Ueno Takayo⁵,Oishi Masayo⁶,Frost Charles¹

Affiliation:

1. Clinical Pharmacology and Pharmacometrics; Bristol-Myers Squibb; Princeton New Jersey USA

2. Ann Arbor Pharmacometrics Group; Ann Arbor Michigan USA

3. Kowalski PMetrics Consulting; Northville Michigan USA

4. Clinical Pharmacology; Pfizer; Groton Connecticut USA

5. Clinical Pharmacology and Pharmacometrics; Bristol-Myers Squibb K.K.; Tokyo Japan

6. Clinical Pharmacology; Pfizer Japan Inc.; Tokyo Japan

Funder

Bristol-Myers Squibb

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/psp4.12347/fullpdf

Reference38 articles.

1. Oral apixaban for the treatment of acute venous thromboembolism;Agnelli;N. Engl. J. Med.,2013

2. Apixaban for extended treatment of venous thromboembolism;Agnelli;N. Engl. J. Med.,2013

3. Apixaban in patients with atrial fibrillation;Connolly;N. Engl. J. Med.,2011

4. Apixaban versus warfarin in patients with atrial fibrillation;Granger;N. Engl. J. Med.,2011

5. Apixaban or enoxaparin for thromboprophylaxis after knee replacement;Lassen;N. Engl. J. Med.,2009

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma apixaban concentrations and thrombin generation assay parameters in response to dose reduction for atrial fibrillation;British Journal of Clinical Pharmacology;2024-08-15

2. Exposure Matching‐Based Pediatric Dose Selection for Drugs with Renal Excretion – Lessons Learned from Pediatric Development of Direct Oral Anticoagulants;Clinical Pharmacology & Therapeutics;2024-08-13

3. Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data;American Journal of Cardiovascular Drugs;2024-08-05

4. Apixaban plasma concentrations in patients with obesity;European Journal of Clinical Pharmacology;2024-06-01

5. Acute severe renal failure in a patient receiving apixaban: a case report;Italian Journal of Medicine;2024-04-09